Roche’s PD-L1 Bladder Cancer Data Show Promise Of New Biomarkers
Executive Summary
Use of The Cancer Genome Atlas subtyping and mutational load analysis complement PD-L1 expression, with potential to improve prediction of response to atezolizumab in the future, according to study in the Lancet.